FDA Approves IMAAVY for Rare Autoimmune Condition

Johnson & Johnson (JNJ) recently received U.S. FDA approval for IMAAVY (nipocalimab-aahu), a treatment for warm autoimmune hemolytic anemia in patients aged 12 and older who are currently or were previously treated with corticosteroids.

This marks the first approved therapy for this rare, life-threatening condition in steroid-treated patients, showcasing Johnson & Johnson's push into targeted autoimmune treatments that spare broad immune suppression.

While IMAAVY's approval adds another niche immunology asset to J&J's portfolio, it does not significantly alter the near-term focus on replacing STELARA revenue or addressing ongoing uncertainty around talc litigation.